This is a great article for those of you who may have to have this treatment.
Colon and breast cancer patients who take Xeloda know the side effect Hand-Foot Syndrome (HFS) or Palmar-Plantar Erythrodysesthesia (PPE). A study at a university in Turkey looked at the use of henna in treating PPE. This webpage tells you how to use it. Reference to the Turkish study is given.
Three years ago, Plastic Surgeon Luis A. Vinas, MD, FACS, stood in his plastic surgery center and listened to an anxious breast reconstruction patient ask him the same question that other patients had asked when they viewed what had been their nipple area:
Doctor, isnt there something that can make my breast whole again?
All that was available was the option of nipple reconstruction. But the results of nipple reconstruction, no matter how skilled the surgeon, were often poor.
Dr. Vinas put together a focus group of breast cancer survivors. Their goal: to help create a beautiful and practical prosthetic nipple that they would want to wear. The prosthetic nipple had to be as lifelike as possible. It had to be thin, resilient, hypo allergenic, and self-adhering. It had to be translucent so a womans skin tone would blend in with the nipples coloration for a perfect match. It had to mold perfectly to the contours of a womans breast for a natural look. And it had to be reusable so women could afford it.
A whole new manufacturing process was developed to give the nipple the natural look and feel that the patients desired. One of the very first women to try ReForma thanked us for our long task with words that will always stay with our company: for the first time in ten years, I feel whole again.
Living Conversations is a celebration of breast cancer survival.
Through the stories of women who are now on the other side of their breast cancer diagnosis and treatment, the site offers hope, inspiration and courage for the many women, family members and network of supporters, affected by this disease.
Living Conversations is a social site where survivors can share their stories through text, photos and videos, and connect with each other. We support the Catalyst for the Cure breast cancer research project at Dana Farber Cancer Institute.
This board is dedicated solely to Hodgkin's Lymphoma survivors and caregivers. It has a very active community, and lots of information on the disease, treatments (both conventional and trials), as well as support in getting through this!
There is also a Non-Hodgkin's forum here as well.
In 2008, the ACS CAN Bus will travel across the country, stopping in hundreds of communities to build the movement to make cancer issues a national priority. ACS CAN will bring the stories of cancer patients, survivors and friends to the presidential candidates to make cancer a priority issue in their administration.
U can sign the bus which my husband and I did in May :)
Go to their web site for more info and to see if the bus will be coming near u.
Make sure that you sign the bus and leave a message.
If you are feeling out of sorts, depressed, alone, unloved please take the time to check this site out and watch the video to find out how much you are loved :)
click on Watch Father's Love Letter Videos (middle), sit back and enjoy!
Joe and Linda Wingo founded Angel Food Ministries in 1994 to provide food for friends and neighbors who were struggling financially. Today, they are still doing the same thing. The Angel Food program now is helping provide food relief to more than 500,000 families each month.
Angel Food Ministries is a non-profit, non-denominational organization dedicated to providing food relief and contributing to benevolent outreaches in communities throughout the United States.
You purchase online or at a participating local church a food packet for $30's (actual value is $60). You can aslo purchase various meat packages. (they also accept food stamps)
If you know of a family in need, senior, or anyone who needs some help this is a great site.
In 2006, Medicare officially recognized cancer chemosensitivity tests as a special test category in Federal Regulations (42 CFR 414.510(b)(3), 71 FR 69705, 12/01/2006). The are now known as Oncologic In Vitro Chemoresponse Assays.
As with any other laboratory tests in cancer medicine, the determination of the efficacy of chemoresponse assays is based on clinical correlations (comparisions of laboratory results with patient response). The "standard" of retrospective correlations between treatment outcomes and laboratory results is sufficient in the case of ALL laboratory tests. It is what established FDA-approval for the test kit.
The decision had been made that the assay is a perfectly appropriate medical service, worthy of coverage on a non-investigational basis. What is of particular significance is that they abandoned the artificial distinction between "resistance" testing and "sensitivity" testing and are providing coverage for the whole FDA-approved kit. Drug "sensitivity" testing is merely a point a little farther along on the very same continuum which "resistance" testing resides.
Cell-based assay tests based on "cell-death" have proven very effective in identifying novel treatment combinations for a variety of cancers. The value of cell-death assays is that they can and do accurately predict clinical outcomes and define novel chemotherapeutic synergies. It can help see what treatments will not have the best opportunity of being successful (resistant) and identify drugs that have the best opportunity of being successful (sensitive).
The current clinical applications of in vitro chemoresponse testing is ever more important with the influx of new "targeted" therapies. Given the technical and conceptual advantages of "functional profiling" of cell-based assays together with their performance and the modest efficacy for therapy prediction on analysis of genome expression, there is reason for renewed interest in these assays for optimized use of medical treatment of malignant disease.
This bio-marker pre-test can help see what treatments have the best opportunity of being successful for "high" risk cancer patients. The test measures the response of "live" tumor cells to drug exposure. Following this exposure, the assays measure both cell metabolism and cell morphology (functional profiling). The integrated effect of the drugs on the whole cell, resulting in a cellular response to the drug, measuring the interaction of the entire genome. Assays based on "cell-death" occur in the entire population of tumor cells.
This cell-based assay technology has been clinically validated for the selection of optimal chemotherapy regimens for individual patients. It is a laboratory analysis based on tumor tissue profiling that uses "fresh" human tumor biopsy or surgical specimen to determine which drugs or combinations of chemotherapeutic agents have the highest likelihood of response for individual cancer patients.
Following the collection of "fresh" tumor cells obtained from surgery or tru-cut needle biopsies, a cell culture assay is performed on the tumor sample to measure drug activity (sensitivity and resistance). This will pinpoint which drug(s) are most effective. Tissue, blood, bone marrow, and ascites and pleural effusions are possibilities, providing tumor cells are present. At least one gram of fresh tissue is needed to perform the tests, and a special kit is obtained in advance from the lab. The treatment program developed through this approach is known as assay-directed therapy.